110 related articles for article (PubMed ID: 12025231)
21. Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma.
Plummer R; Lorigan P; Brown E; Zaucha R; Moiseyenko V; Demidov L; Soriano V; Chmielowska E; Andrés R; Kudryavtseva G; Kahatt C; Szyldergemajn S; Extremera S; de Miguel B; Cullell-Young M; Calvert H
Br J Cancer; 2013 Sep; 109(6):1451-9. PubMed ID: 23989947
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of recombinant interferon-alpha with BCNU, cisplatin, DTIC and tamoxifen in advanced malignant melanoma.
Feun LG; Savaraj N; Moffat F; Robinson D; Liebmann A; Hurley J; Raub WA; Richman SP
Melanoma Res; 1995 Aug; 5(4):273-6. PubMed ID: 7496164
[TBL] [Abstract][Full Text] [Related]
23. A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma.
Tarhini AA; Kirkwood JM; Gooding WE; Moschos S; Agarwala SS
Cancer; 2008 Oct; 113(7):1632-40. PubMed ID: 18720480
[TBL] [Abstract][Full Text] [Related]
24. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.
Atkins MB; Gollob JA; Sosman JA; McDermott DF; Tutin L; Sorokin P; Parker RA; Mier JW
Clin Cancer Res; 2002 Oct; 8(10):3075-81. PubMed ID: 12374674
[TBL] [Abstract][Full Text] [Related]
25. Vinblastin-carboplatin for metastatic cutaneous melanoma as first-line chemotherapy and in dacarbazine failures: a single-center study.
Jelić S; Babović N; Stamatović L; Kreacić M; Matković S; Popov I
Med Oncol; 2001; 18(3):189-95. PubMed ID: 11917943
[TBL] [Abstract][Full Text] [Related]
26. Preliminary experience with high-dose cisplatin, reduced glutathione and natural interferon-alpha in dacarbazine-resistant malignant melanoma.
Bajetta E; Rimassa L; Carnaghi C; Del Vecchio M; Celio L; Cassata A
Tumori; 1998; 84(1):48-51. PubMed ID: 9619714
[TBL] [Abstract][Full Text] [Related]
27. Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patients.
Socinski MA; Mudd PN; Radomski KM; Steagall A; Lawrence P; Bernard S; Letrent SP; Gonzalez P; Brouwer KL
Anticancer Drugs; 1998 Aug; 9(7):611-9. PubMed ID: 9773805
[TBL] [Abstract][Full Text] [Related]
28. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
[TBL] [Abstract][Full Text] [Related]
29. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Edelman MJ; Meyers FJ; Houston J; Lauder I
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
[TBL] [Abstract][Full Text] [Related]
30. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
[TBL] [Abstract][Full Text] [Related]
31. Biochemotherapy with carmustine, cisplatin, dacarbazine, tamoxifen and low-dose interleukin-2 for patients with metastatic malignant melanoma.
Su PJ; Chen JS; Liaw CC; Chang HK; Wang HM; Yang TS; Lin YC; Liau CT; Yang HY; Yeh KY; Ho MM; Chang NJ; Wang CH; Chang JW
Chang Gung Med J; 2011; 34(5):478-86. PubMed ID: 22035892
[TBL] [Abstract][Full Text] [Related]
32. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.
Legha SS; Ring S; Eton O; Bedikian A; Buzaid AC; Plager C; Papadopoulos N
J Clin Oncol; 1998 May; 16(5):1752-9. PubMed ID: 9586888
[TBL] [Abstract][Full Text] [Related]
33. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.
Langer CJ; Millenson M; Rosvold E; Litwin S; McAleer CA; Bonjo CA; Ozols R
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-81-S12-88. PubMed ID: 9331128
[TBL] [Abstract][Full Text] [Related]
34. Combination chemotherapy (dacarbazine, carmustine, cisplastin, and tamoxifen) in advanced melanoma.
Tan EH; Ang PT
Singapore Med J; 1996 Apr; 37(2):165-7. PubMed ID: 8942255
[TBL] [Abstract][Full Text] [Related]
35. Dacarbazine DTIC and carboplatin as an outpatient treatment for disseminated malignant melanoma.
Nieboer P; Mulder NH; Van Der Graaf WT; Willemse PH; Hospers GA
Anticancer Res; 2001; 21(4B):3115-6. PubMed ID: 11712820
[TBL] [Abstract][Full Text] [Related]
36. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.
McDermott DF; Mier JW; Lawrence DP; van den Brink MR; Clancy MA; Rubin KM; Atkins MB
Clin Cancer Res; 2000 Jun; 6(6):2201-8. PubMed ID: 10873069
[TBL] [Abstract][Full Text] [Related]
37. High-dose cisplatin plus dacarbazine in the treatment of metastatic melanoma.
Murren JR; DeRosa W; Durivage HJ; Davis C; Makuch R; Portlock CS
Cancer; 1991 Mar; 67(6):1514-7. PubMed ID: 2001539
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
[TBL] [Abstract][Full Text] [Related]
39. Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients.
Homsi J; Bedikian AY; Kim KB; Papadopoulos NE; Hwu WJ; Mahoney SL; Hwu P
Melanoma Res; 2009 Aug; 19(4):238-42. PubMed ID: 19521262
[TBL] [Abstract][Full Text] [Related]
40. Combination chemotherapy with docetaxel and irinotecan in metastatic malignant melanoma.
Tas F; Camlica H; Kurul S; Aydiner A; Topuz E
Clin Oncol (R Coll Radiol); 2003 May; 15(3):132-5. PubMed ID: 12801051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
